Skip to main content
Passa alla visualizzazione normale.

GIUSEPPE SALEMI

Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study

  • Authors: Clerico, M; De Mercanti, S; Piazza, F; Gned, D; Morra, V; Lanzillo, R; Amato, L; Quarantelli, M; Ghezzi, A; Bianchi, A; Baroncini, D; Gibbin, M; Vargas, J; Salemi, G; Realmuto, S; Ferrò, MT; Vitetta, F; Sola, P; Paolicelli, D; Trojano, M; Durelli, L
  • Publication year: 2013
  • Type: Proceedings
  • OA Link: http://hdl.handle.net/10447/73012